[go: up one dir, main page]

CY1109626T1 - Ενωσεις με ιδιοτητες αποδεσμευσης αυξητικης ορμονης - Google Patents

Ενωσεις με ιδιοτητες αποδεσμευσης αυξητικης ορμονης

Info

Publication number
CY1109626T1
CY1109626T1 CY20091101195T CY091101195T CY1109626T1 CY 1109626 T1 CY1109626 T1 CY 1109626T1 CY 20091101195 T CY20091101195 T CY 20091101195T CY 091101195 T CY091101195 T CY 091101195T CY 1109626 T1 CY1109626 T1 CY 1109626T1
Authority
CY
Cyprus
Prior art keywords
components
growth hormone
hormone releasing
releasing properties
bis substituted
Prior art date
Application number
CY20091101195T
Other languages
English (en)
Inventor
Thomas Kruse Hansen
Michael Ankersen
Original Assignee
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S
Publication of CY1109626T1 publication Critical patent/CY1109626T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A61P5/08—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH for decreasing, blocking or antagonising the activity of the anterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται με καινοφανείς ενώσεις, ειδικότερα δε με ενώσεις 4,4-δις υποκατεστημένης και 3,3-δις υποκατεστημένης πιπεριδίνης, με συνθέσεις που τις περιέχουν, και με την χρήση αυτών για την αγωγή ιατρικών διαταραχών που προκύπτουν από μία ανεπάρκεια σε αυξητική ορμόνη.
CY20091101195T 1998-05-11 2009-11-12 Ενωσεις με ιδιοτητες αποδεσμευσης αυξητικης ορμονης CY1109626T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK63698 1998-05-11
DKPA199800875 1998-07-01
EP99919125A EP1077941B1 (en) 1998-05-11 1999-05-10 Compounds with growth hormone releasing properties

Publications (1)

Publication Number Publication Date
CY1109626T1 true CY1109626T1 (el) 2014-08-13

Family

ID=26064372

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091101195T CY1109626T1 (el) 1998-05-11 2009-11-12 Ενωσεις με ιδιοτητες αποδεσμευσης αυξητικης ορμονης

Country Status (23)

Country Link
EP (1) EP1077941B1 (el)
JP (2) JP4142253B2 (el)
KR (1) KR100593601B1 (el)
CN (1) CN1142911C (el)
AT (1) ATE439346T1 (el)
AU (1) AU757217B2 (el)
BR (1) BR9910329A (el)
CA (1) CA2329881C (el)
CY (1) CY1109626T1 (el)
CZ (1) CZ301276B6 (el)
DE (1) DE69941255D1 (el)
DK (1) DK1077941T3 (el)
ES (1) ES2331102T3 (el)
HU (1) HUP0102071A3 (el)
IL (2) IL139090A0 (el)
NO (1) NO318080B1 (el)
PL (1) PL194560B1 (el)
PT (1) PT1077941E (el)
RU (1) RU2243215C2 (el)
SI (1) SI1077941T1 (el)
TW (1) TWI222969B (el)
UA (1) UA72210C2 (el)
WO (1) WO1999058501A1 (el)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ20011872A3 (cs) 1999-09-29 2002-03-13 Ortho-Mcneil Pharmaceutical, Inc. Isonipekotamidy pro léčbu onemocnění zprostředkovaných integriny
UA73530C2 (uk) 1999-11-10 2005-08-15 Ново Нордіск А/С Сполука з властивостями вивільнювати гормон росту
US20010020012A1 (en) * 2000-02-01 2001-09-06 Andersen Maibritt Bansholm Use of compounds for the regulation of food intake
AU2002230665A1 (en) 2000-12-06 2002-06-18 Sepracor, Inc. 4,4-disubstituted piperidines for use as dopamine, serotonin and norepinephrine ligands
JP2005511475A (ja) 2001-03-02 2005-04-28 ブリストル−マイヤーズ スクイブ カンパニー メラノコルチン受容体のモジュレーターとして有用な化合物及びそれを含む製薬組成物
DE10113604A1 (de) * 2001-03-20 2002-10-24 Ibfb Gmbh Privates Inst Fuer B Verfahren zur Spaltung des humanen Wachstumshormons GH
JP2004529918A (ja) 2001-04-09 2004-09-30 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド インテグリンに由来する疾患の治療のためのキナゾリンおよびキナゾリン類似化合物
US6911447B2 (en) * 2001-04-25 2005-06-28 The Procter & Gamble Company Melanocortin receptor ligands
FR2827518B1 (fr) * 2001-07-17 2005-07-08 Sod Conseils Rech Applic Utilisation d'extraits de ginkgo biloba pour preparer un medicament destine a traiter la sarcopenie
WO2003013571A1 (en) 2001-08-10 2003-02-20 Palatin Technologies, Inc. Peptidomimetics of biologically active metallopeptides
US7026335B2 (en) 2002-04-30 2006-04-11 The Procter & Gamble Co. Melanocortin receptor ligands
EP1407779A1 (en) 2002-10-10 2004-04-14 Gastrotech A/S Use of ghrelin for treating low body weight and body fat in gastrectomized individuals
TW200504033A (en) 2002-10-23 2005-02-01 Procter & Gamble Melanocortin receptor ligands
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
US20050261201A1 (en) * 2004-03-30 2005-11-24 Rejuvenon Corporation Method of reducing C-reactive protein using growth hormone secretagogues
CN102584937B (zh) * 2004-06-29 2017-03-01 赫尔辛医疗股份公司 (3r)‑1‑(2‑甲基丙氨酰‑d‑色氨酰)‑3‑(苯甲基)‑3‑哌啶羧酸1，2，2‑三甲基酰肼的晶形
EP1789067B8 (en) * 2004-08-12 2012-08-15 Helsinn Healthcare S.A. Use of growth hormone secretagogues for stimulating the motility of the gastrointestinal system
CU23558A1 (es) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento
CA2656398A1 (en) * 2006-06-30 2008-01-10 Schering Corporation Substituted piperidines that increase p53 activity and the uses thereof
CN101657436A (zh) 2007-02-09 2010-02-24 特兰齐姆制药公司 大环生长素释放肽受体调节剂及其使用方法
WO2012131090A1 (en) 2011-03-31 2012-10-04 Galderma Research & Development Method for treatment of xeroderma pigmentosum
CN114805305B (zh) * 2022-04-20 2024-04-26 成都诺和晟泰生物科技有限公司 一种化合物及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995013069A1 (en) * 1993-11-09 1995-05-18 Merck & Co., Inc. Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone
US5492916A (en) * 1993-12-23 1996-02-20 Merck & Co., Inc. Di- and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US5721250A (en) * 1993-12-23 1998-02-24 Merck & Co. Inc. Di-and tri-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone
US5559128A (en) * 1995-04-18 1996-09-24 Merck & Co., Inc. 3-substituted piperidines promote release of growth hormone
WO1996035713A1 (en) * 1995-05-08 1996-11-14 Pfizer, Inc. Dipeptides which promote release of growth hormone
EP0828754B1 (en) * 1995-05-29 2005-02-02 Pfizer Inc. Dipeptides which promote release of growth hormone
GB2308064A (en) * 1995-10-31 1997-06-18 Merck & Co Inc Treatment of congestive heart failure with a growth hormone secretagogue
WO1997036873A1 (en) * 1996-04-03 1997-10-09 Merck & Co., Inc. Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone
WO1998003473A1 (en) * 1996-07-22 1998-01-29 Novo Nordisk A/S Compounds with growth hormone releasing properties
WO1998010653A1 (en) * 1996-09-13 1998-03-19 Merck & Co., Inc. Piperidines, pyrrolidines and hexahydro-1h-azepines promote release of growth hormone
WO1998016527A1 (en) * 1996-10-15 1998-04-23 Fujisawa Pharmaceutical Co., Ltd. Benzoxepine derivatives which promote release of growth hormone

Also Published As

Publication number Publication date
PL194560B1 (pl) 2007-06-29
IL139090A (en) 2007-03-08
ATE439346T1 (de) 2009-08-15
EP1077941A1 (en) 2001-02-28
CA2329881A1 (en) 1999-11-18
TWI222969B (en) 2004-11-01
AU757217B2 (en) 2003-02-06
HUP0102071A2 (hu) 2002-03-28
AU3701099A (en) 1999-11-29
CN1300281A (zh) 2001-06-20
JP2008156372A (ja) 2008-07-10
CZ20004129A3 (en) 2001-06-13
UA72210C2 (uk) 2005-02-15
NO318080B1 (no) 2005-01-31
RU2243215C2 (ru) 2004-12-27
JP4938708B2 (ja) 2012-05-23
HUP0102071A3 (en) 2002-06-28
JP4142253B2 (ja) 2008-09-03
KR100593601B1 (ko) 2006-06-28
KR20010043422A (ko) 2001-05-25
WO1999058501A1 (en) 1999-11-18
ES2331102T3 (es) 2009-12-21
CZ301276B6 (cs) 2009-12-30
SI1077941T1 (sl) 2010-01-29
CA2329881C (en) 2010-03-16
BR9910329A (pt) 2001-01-30
DE69941255D1 (de) 2009-09-24
DK1077941T3 (da) 2009-12-07
EP1077941B1 (en) 2009-08-12
NO20005668L (no) 2001-01-10
PT1077941E (pt) 2010-07-01
NO20005668D0 (no) 2000-11-10
PL344042A1 (en) 2001-09-24
CN1142911C (zh) 2004-03-24
IL139090A0 (en) 2001-11-25
JP2004500312A (ja) 2004-01-08

Similar Documents

Publication Publication Date Title
CY1109626T1 (el) Ενωσεις με ιδιοτητες αποδεσμευσης αυξητικης ορμονης
CY1106467T1 (el) Ελεγχομενη συνθεση ζιπρασιδονης
DE69725825D1 (de) 5-HT1F-Agonisten
SE9802729D0 (sv) Novel Compounds
EA199700032A1 (ru) Дезинфицирующий состав "велтолен"
DE69831409D1 (de) Chalcon-derivate mit antiproliferativer aktivität
SE9802937D0 (sv) Novel compounds
FI973221A0 (fi) 1-aryyli-2-asyyliammo-etaaniyhdisteitä ja niiden käyttö neurokiniiniantagonisteina, erityisesti neurokiniini 1 antagonisteina
IL126235A (en) Compounds with growth hormone releasing properties, pharmaceutical compositions comprising them and their use
ES2177024T3 (es) Empleo de la fanquinoma para el tratamiento de la enfermedaad de alzheimer.
DK1100824T3 (da) Forbindelser med væksthormonfrigivende egenskaber
ID25478A (id) Agonis 5-ht1f
ES2150418T3 (es) Composiciones farmaceuticas que comprenden calcitonina.
NO20012169L (no) Forbindelser med veksthormonfrigjörende egenskaper
TR200101729T2 (tr) IL-5 engelleyici 6-azaurasil türevleri
ATE245430T1 (de) Zusammensetzung enthaltend eugenol und polyphenole, verwendung einer solchen zusammensetzung zur wundheilung